# Natera, Inc.
> Natera is a global leader in cell-free DNA (cfDNA) testing, specializing in genetic testing for prenatal health, oncology, and organ health. The company utilizes proprietary molecular biology and bioinformatics to provide non-invasive insights into human health and disease management.
- URL: https://optimly.ai/brand/natera
- Slug: natera
- BAI Score: 88/100
- Archetype: Challenger
- Category: Biotechnology / Healthcare
- Last Analyzed: April 10, 2026
- Part of: Independent Publicly Traded (https://optimly.ai/brand/independent-publicly-traded)
## Competitors
- Guardant Health (https://optimly.ai/brand/guardant-health)
## Also Referenced By
- Ambry Genetics (https://optimly.ai/brand/ambry-genetics)
- Invitae (https://optimly.ai/brand/invitae)
- Invitae Invitae (https://optimly.ai/brand/invitae-invitae)
- Adaptive Biotechnologies (https://optimly.ai/brand/adaptive-biotechnologies)
- Myriad Genetics, Inc. (https://optimly.ai/brand/myriad-genetics)
- Integrated Genetics (https://optimly.ai/brand/labcorp-integrated-genetics)
## Buyer Intent Signals
Problems: Standard OB/GYN Care: Standard prenatal care through obstetricians without genetic screening support. | Invasive Diagnostic Procedures: Invasive diagnostic procedures like Amniocentesis or Chorionic Villus Sampling (CVS).
Solutions: non-invasive prenatal testing providers | MRD testing for colorectal cancer | personalized liquid biopsy oncology | SNP-based genetic screening | kidney transplant rejection blood test | Hospital Labs: Hospital-based pathology and localized oncology screening services.